Sanofi's Q3 2025 earnings report reveals mixed performance with revenue growth driven by blockbuster drug sales, but conflicting data highlights need for scrutiny.

viernes, 24 de octubre de 2025, 5:52 am ETnull min de lectura

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios